People: Cytori Therapeutics Inc (CYTX.W)

CYTX.W on CBOE When Trading NASDAQ Global Select Market

2.55USD
23 May 2013
Price Change (% chg)

$0.02 (+0.79%)
Prev Close
$2.53
Open
$2.52
Day's High
$2.55
Day's Low
$2.47
Volume
700
Avg. Vol
397
52-wk High
$4.78
52-wk Low
$2.06

Search Stocks

Summary

Name Age Since Current Position

Lloyd Dean

 62 2011 Independent Chairman of the Board

Marc Hedrick

 50 2004 President, Director

Christopher Calhoun

 46 2005 Chief Executive Officer, Director

Mark Saad

 42 2004 Chief Financial Officer

Seijiro Shirahama

 58 2007 President , Asia Pacific

Clyde Shores

 52 2011 Executive Vice President - Marketing & Sales

Steven Kesten

 2013 Executive Vice President, Chief Medical Officer

Richard Hawkins

 63 2007 Independent Director

Paul Hawran

 60 2005 Independent Director

E. Carmack Holmes

 74 2003 Independent Director

David Rickey

 56 1999 Independent Director

Tommy Thompson

 71 2011 Independent Director

Tom Baker

 IR Contact
» Insider Trading

Biographies

Name Description

Lloyd Dean

 Mr. Lloyd H. Dean is an Independent Chairman of the Board of Cytori Therapeutics, Inc. Mr. Dean has served as the President/Chief Executive Officer and Director of Dignity Health, formerly Catholic Healthcare West, the eighth healthcare systems in the United States, located in San Francisco, California, since 2000. Previously, Mr. Dean held positions as the executive vice president and chief operating officer of Advocate Health Care, and various management positions with the Upjohn Company. Mr. Dean is also chairman and director of California Health Association of USA, a director of Mercy Housing Inc., a director of Wells Fargo & Company, and chair of the board of directors of the Bay Area Council. He is a member of McKesson’s Advisory Board, the Health Research and Development Institute, San Francisco Mayor Gavin Newsom’s Universal Healthcare Council, Governor Schwarzenegger’s California Commission for Jobs and Economic Growth, and the San Francisco Committee on JOBS. Mr. Dean holds a Master’s Degree in education from Western Michigan University and also is a graduate of Pennsylvania State University’s Executive Management Program.

Marc Hedrick

 Dr. Marc H. Hedrick, M.D., is President, Director of Cytori Therapeutics Inc. He was appointed President of the Company in May 2004, and joined the company as Chief Scientific Officer, Medical Director and Director in October 2002. In December 2000, Dr. Hedrick co-founded and served as President and Chief Executive Officer and Director of StemSource, Inc., a company specializing in stem cell research and development, which was acquired by the Company in 2002. He is a plastic surgeon and is a former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). From 1998 until 2005, he directed the Laboratory of Regenerative Bioengineering and Repair for the Department of Surgery at UCLA. Dr. Hedrick earned his M.D. degree from University of Texas Southwestern Medical School, Dallas and an M.B.A. from UCLA Anderson School of Management.

Christopher Calhoun

 Mr. Christopher J. Calhoun is Chief Executive Officer and Director of Board of Cytori Therapeutics Inc. He is a co-founder of the Company and has served as Chief Executive Officer and Director since 1997. Mr. Calhoun also served as President from April 2002 to May 2005 and from 1996 to 1998. He is a co-inventor on multiple U.S. and international patents for medical devices and implant instrumentation, and was involved in research and management for the Plastic Surgery Bone Histology and Histometry Laboratory at the University of California, San Diego. Mr. Calhoun is a co-founder and Chairman of the Board of Leonardo MD, and previously served on the Board of Directors of StemSource, Inc. which was acquired by the Company in 2002. Mr. Calhoun earned a B.A. from the University of California, San Diego and an M.B.A from the University of Phoenix.

Mark Saad

 Mr. Mark E. Saad is Chief Financial Officer of Cytori Therapeutics Inc. Previously, Mr. Saad served as Chief Operating Officer of UBS, Healthcare Investment Banking, New York, where he was responsible for global investment banking operations. Upon joining UBS in 1999, Mr. Saad served as Director/Executive Director covering life sciences sectors - biotechnology and medical devices. Prior to joining UBS, he held the position of Financial Analyst/Associate with Salomon, Smith Barney, Healthcare Investment Banking, New York, where he managed public and private transactions. Mr. Saad holds a B.A. from Villanova University, Philadelphia, PA.

Seijiro Shirahama

 Mr. Seijiro N. Shirahama is President, Asia Pacific of Cytori Therapeutics Inc. Mr. Shirahama had served as Senior Vice President – Asia Pacific since November 2006, and as Vice President – Asia Pacific, from September 2002 to November 2006. Prior to that, from May 1999 to August 2002, Mr. Shirahama was President of Touchmetrics K.K., a diagnostic ultrasound firm. He held executive positions with Bristol-Myers Squibb K.K. from April 1997 to October 1998, and from March 1995 until March 1997, was the General Manager for Baxter Biotech Group in Tokyo, Japan. Mr. Shirahama holds a B.A. from Kanagawa University in Yokohama, Japan and an M.A. from the University of San Francisco.

Clyde Shores

 Mr. Clyde W. Shores is an Executive Vice President of Marketing & Sales of Cytori Therapeutics Inc. Mr. Shores has 28 years marketing and sales experience in pharmaceuticals, biologics, devices, and diagnostics. Prior to joining Cytori Therapeutics, Mr. Shores served as Vice President of Global Marketing for Baxter International’s $2 billion Renal Division. Prior to Baxter, Mr. Shores held various senior marketing and sales positions at Amgen, Abbott Laboratories, Prometheus Laboratories and deCODE Genetics. Mr. Shores joined Amgen in 1990 and held a number of leadership positions during the company’s rapid expansion in the 1990’s from $298MM sales and 1,100 employees to $3.4B and more than 6,300 employees in 1999. During his tenure at Amgen, Mr. Shores led multiple innovative marketing initiatives for Amgen’s blockbuster oncology and stem cell therapy drugs Neupogen® and Neulasta® which have grown to more than $4.8B in annual revenues. Mr. Shores earned a B.S. degree from the Anderson School of Management at the University of New Mexico.

Steven Kesten

 Dr. Steven Kesten, M.D. has been appointed as the Executive Vice President and Chief Medical Officer of Cytori Therapeutics Inc. Most recently Dr. Kesten served as Vice President and Chief Medical Officer at Uptake Medical, where he oversaw the completion of the VAPOR trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical's device, InterVapor(R) . He previously served for more than ten years at Boehringer Ingelheim, most recently as the Vice President in Medicine for Marketed Products for respiratory disease. During his tenure, Dr. Kesten was responsible for the development and execution of multiple clinical trials and took the medical lead in the global registration, branding and reimbursement of the drug Spiriva(R) , a $3 billion worldwide product for chronic obstructive pulmonary disease. Dr. Kesten lived in Germany for three years and is experienced in European regulatory affairs and reimbursement strategies. In addition, Dr. Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke's Medical Center in Chicago. Dr. Kesten received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.

Richard Hawkins

 Mr. Richard J. Hawkins is an Independent Director of Cytori Therapeutics Inc. In 1982, Mr. Hawkins founded Pharmaco, a clinical research organization (CRO) that merged with the predecessor of PPD-Pharmaco in 1991 and is one of the CROs in the world today. In 1992, Mr. Hawkins co-founded Sensus Drug Development, which developed and received regulatory approval for SOMAVERT®, a growth hormone antagonist approved for the treatment of acromegaly, which is now marketed by Pfizer in both the United States and Europe, and he served as Chairman until 2000. In 1994, Mr. Hawkins co-founded Corning Biopro, a contract protein manufacturing firm where he served on the Board until 2000. In September 2003 Mr. Hawkins founded LabNow, Inc., a privately held company that develops lab-on-a-chip sensor technology, where he served as the Chairman and CEO until October 2009. Mr. Hawkins has served on the Board of SciClone Pharmaceuticals, Inc. since October 2004. In February 2011, Mr. Hawkins became CEO, and is currently CEO, of Lumos Pharma, Inc., a start-up pharma company. He served on the Presidential Advisory Committee for the Center for Nano and Molecular Science and Technology at the University of Texas in Austin, and was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas. Mr. Hawkins graduated cum laude with a B.S. in Biology from Ohio University.

Paul Hawran

 Mr. Paul W. Hawran, CPA., is an Independent Director of Cytori Therapeutics Inc. Mr. Hawran has held various strategic, financial and operational positions in the health care industry for over 30 years. Currently, Mr. Hawran is a Founder and President and CEO of Ascendant MDx, a molecular diagnostic testing company focused on women’s health care, since November, 2010. Prior to Ascendant MDx, Mr. Hawran was the Chief Financial Officer of Sequenom, Inc., a publicly traded genetics company, from April, 2007 to September, 2009, served on their Board of Directors from August, 2006 to February, 2007 and was the Chairman of the Audit Committee of the Board of Directors. Mr. Hawran also served as a Founder, Executive Vice President and Chief Financial Officer of Neurocrine Biosciences, Inc. from May 1993 through September 2006, and as a Senior Advisor to Neurocrine from September 2006 through April 2007. Neurocrine Biosciences, Inc. is a publicly traded company engaged in pharmaceutical drug development. Mr. Hawran was employed by SmithKline Beecham (now Glaxo SmithKline) from July 1984 to May 1993, most recently as Vice President and Treasurer. Prior to joining SmithKline in 1984, he held various financial positions at Warner Communications (now Time Warner) involving corporate finance and financial planning and forecasting. Mr. Hawran earned a B.S. in Finance from St. John's University and an M.S. in Taxation from Seton Hall University. He is a Certified Public Accountant (currently inactive) and is a member of the American Institute of Certified Public Accountants.

E. Carmack Holmes

 Dr. E. Carmack Holmes, M.D., is an Independent Director of Cytori Therapeutics Inc. Dr. Holmes served as the Surgeon-in-Chief of the University of California Los Angeles (UCLA) Medical Center and held the position of William P. Longmire, Jr. Professor and Chairman, Department of Surgery, UCLA School of Medicine, from 1994 to 2004. He joined UCLA in 1973 and has held professorial positions in the Divisions of Cardiothoracic Surgery and Surgical Oncology for over 30 years. He served as Vice-Chairman for five years prior to holding the positions of Chairman and Surgeon-in-Chief. He also founded and served as Director of the Wunderman Foundation Cell Growth Regulation Program. Dr. Holmes is the recipient of numerous awards and grants and professional memberships including the American Surgical Association, the American College of Surgeons and the Association for Academic Surgeons. He has authored 250 medical publications throughout his career and has been an internationally invited lecturer for over 25 years. His surgical training was conducted at Johns Hopkins University and the National Cancer Institute at the National Institutes of Health (NIH). Dr. Holmes also served on the Board of Directors of StemSource, Inc. which was acquired by the Company in 2002. Dr. Holmes graduated from Duke University and holds an M.D. from the University of North Carolina Medical School.

David Rickey

 Mr. David M. Rickey is an Independent Director of Cytori Therapeutics Inc. Mr. Rickey was President and Chief Executive Officer of Applied Micro Circuits Corporation (AMCC), which provides high-performance, high-bandwidth silicon solutions for optical networks, from February 1996 to March 2005. Mr. Rickey served on the Board of Directors of AMCC from February 1996 to March 2005, and as its Chairman of the Board from August 2000 to March 2005. Mr. Rickey also served as a Director of AMI Semiconductor, Inc. from 2000 to 2006 and was a Director of Netlist, Inc. from 2005 to 2008, as well as several private technology companies. He holds a B.S. from Marietta College, a B.S. from Columbia University and an M.S. from Stanford University.

Tommy Thompson

 Gov., Hon. Tommy G. Thompson, J.D., is an Independent Director of Cytori Therapeutics, Inc. Mr. Thompson was a partner at the law firm of Akin Gump Strauss Hauer & Feld from March 2005 to January 2012. He served as U.S Department of Health and Human Services Secretary from January 2001 to January 2005, and was Governor of Wisconsin from January 1987 to January 2001. Mr. Thompson was the Chairman of the Board of Logistics Health, Inc., having been President from February 2005 to January 2011. Mr. Thompson has served as a Director of C.R. Bard since August 2005; a Director of CareView Communications, Inc. since July 2005; a Director of Centene Corporation since April 2005 and a Director of United Therapeutics Corporation since February 2011. He also served as Chairman of the Board of AGA Medical Corporation from July 2005 to November 2011. He is a recipient of the prestigious Horatio Alger Award and has served as chairman of the National Governors’ Association, the Education Commission of the States, and the Midwestern Governors’ Conference. Mr. Thompson received both his B.S. and his J.D. from the University of Wisconsin-Madison and also served in the Wisconsin National Guard and the Army Reserve.

Tom Baker

Basic Compensation

Name Fiscal Year Total

Lloyd Dean

 --

Marc Hedrick

 894,243

Christopher Calhoun

 1,152,450

Mark Saad

 825,876

Seijiro Shirahama

 856,571

Clyde Shores

 662,598

Steven Kesten

 --

Richard Hawkins

 --

Paul Hawran

 --

E. Carmack Holmes

 --

David Rickey

 --

Tommy Thompson

 --

Tom Baker

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Lloyd Dean

 0 0

Marc Hedrick

 295,630 1,287,564

Christopher Calhoun

 980,000 4,291,115

Mark Saad

 260,000 1,156,800

Seijiro Shirahama

 0 0

Clyde Shores

 0 0

Steven Kesten

 0 0

Richard Hawkins

 0 0

Paul Hawran

 0 0

E. Carmack Holmes

 0 0

David Rickey

 0 0

Tommy Thompson

 0 0

Tom Baker

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks